Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study
出版年份 2021 全文链接
标题
Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study
作者
关键词
-
出版物
Cancer Medicine
Volume 10, Issue 22, Pages 8114-8126
出版商
Wiley
发表日期
2021-10-09
DOI
10.1002/cam4.4326
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Knockdown of AKT3 Activates HER2 and DDR Kinases in Bone-Seeking Breast Cancer Cells, Promotes Metastasis In Vivo and Attenuates the TGFβ/CTGF Axis
- (2021) Nico Hinz et al. Cells
- The Impact of Primary Tumor Surgery on Survival in HER2 Positive Stage IV Breast Cancer Patients in the Current Era of Targeted Therapy
- (2020) Ross Mudgway et al. ANNALS OF SURGICAL ONCOLOGY
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
- (2020) Sandra M Swain et al. LANCET ONCOLOGY
- Breast cancer is a systemic disease optimally treated by a multidisciplinary team
- (2020) Nadia Harbeck Nature Reviews Disease Primers
- Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
- (2020) Cristina Saura et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of brain metastases according to molecular subtypes
- (2020) Riccardo Soffietti et al. Nature Reviews Neurology
- Breast Subtypes and Prognosis of Breast Cancer Patients With Initial Bone Metastasis: A Population-Based Study
- (2020) Deyue Liu et al. Frontiers in Oncology
- Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2019) F Cardoso et al. ANNALS OF ONCOLOGY
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
- (2019) Rashmi K. Murthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01
- (2018) Atilla Soran et al. ANNALS OF SURGICAL ONCOLOGY
- Bone metastasis pattern in initial metastatic breast cancer: a population-based study
- (2018) Zhenchong Xiong et al. Cancer Management and Research
- Metastatic bone disease: Pathogenesis and therapeutic options
- (2018) Stella D'Oronzo et al. Journal of Bone Oncology
- Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
- (2017) Véronique Diéras et al. LANCET ONCOLOGY
- Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study
- (2017) Qi Wu et al. Oncotarget
- Dietary factors and polymorphisms in vitamin D metabolism genes: the risk and prognosis of colorectal cancer in northeast China
- (2017) Chen Gong et al. Scientific Reports
- Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer
- (2016) Joachim Diessner et al. BMC CANCER
- Comparison of HER2 Expression in Primary Tumor and Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients
- (2016) Brigitte Rack et al. ONCOLOGY
- Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial
- (2015) Rajendra Badwe et al. LANCET ONCOLOGY
- US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
- (2014) Nadia Howlader et al. JNCI-Journal of the National Cancer Institute
- The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse
- (2013) A. D. Hartkopf et al. BREAST CANCER RESEARCH AND TREATMENT
- Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome
- (2013) Dorien J. A. Lobbezoo et al. BREAST CANCER RESEARCH AND TREATMENT
- Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden
- (2013) Omar M. Rashid et al. SURGERY
- Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients
- (2011) Brigitte Rack et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Metastatic Behavior of Breast Cancer Subtypes
- (2010) Hagen Kennecke et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started